Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 1, 1997, Pages 83-97

  Schoemaker, H ^a   Claustre, Y ^a   Fage, D ^a   Rouquier, L ^a   Chergui, K ^b   Curet, O ^a   Oblin, A ^a   Gonon, F ^b   Carter, C ^a   Benavides, J ^a   Scatton, B ^a  

^a SANOFI   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ACETYLCHOLINE; AMISULPRIDE; BENZAMIDE DERIVATIVE; CLONIDINE; DESIPRAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; FLUMAZENIL; GLYCINE; IFENPRODIL; LIGAND; MEPYRAMINE; MESULERGINE; NEUROLEPTIC AGENT; PRAZOSIN; PRESYNAPTIC RECEPTOR; QUIPAZINE; RACLOPRIDE; SEROTONIN; SPIPERONE; STRYCHNINE; TRITIUM; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOSE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; LIGAND BINDING; LIMBIC SYSTEM; MALE; MOUSE; NEUROCHEMISTRY; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ACETYLCHOLINE; ANIMALS; ANTIPSYCHOTIC AGENTS; CATTLE; CHO CELLS; CRICETINAE; DOPAMINE; DOPAMINE ANTAGONISTS; HUMANS; LIMBIC SYSTEM; MALE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, PRESYNAPTIC; SULPIRIDE; SWINE;

EID: 8244235137     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (112)

1. 3 receptor antagonist and antiemetic properties. Eur. J. Pharmacol. 232: 139-145, 1993.
2. ARBILLA, S., DEPOORTERE, H., GEORGE, P. AND LANGER, S. Z.: Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats. Naunyn Schmiedebergs Arch. Pharmacol. 330: 248-251, 1985.
3. ARBILLA, S. AND LANGER, S. Z.: Differential effects of the stereoisomers of 3PPP on dopaminergic and cholinergic neurotransmission in superfused slices of the corpus striatum. Naunyn Schmiedebergs Arch. Pharmacol. 327: 6-13, 1984.
4. 3 receptors. Eur. J. Pharmacol. 305: 119-122, 1996.
5. ARETHA, C. W., SINHA, A. AND GALLOWAY, M. P.: Dopamine D3-preferring ligands act at synthesis modulating autoreceptors. J. Pharmacol. Exp. Ther. 274: 609-613, 1995.
6. ASANO, M., MIYAUCHI, T., KATO, T., FUJIMORI, K. AND YAMAMOTO, K.: Determination of acetylcholine and choline in rat brain tissue by liquid chromatography/electrochemistry using an immobilized enzyme post column reactor. J. Liquid Chromatogr. 9: 199-215, 1986.
7. 3H-SCH 23390, a selective D-l receptor antagonist ligand, in rat striatum. Life Sci. 35: 1885-1893, 1984.
8. BISCHOFF, S.: Limbic selective neuroleptics. Clin. Neuropharmacol. 15S: 265-266, 1992.
9. 125I]-iodoaulpride. Synapse 19: 1-13, 1995.
10. BOYER, P., LECRUBIER, Y. AND PUECH, A. J.: Treatment of positive and negative symptoms: Pharmacologic approaches. Mod. Probl. Pharmacopsychiat. 24: 152-174, 1990.
11. BOYER, P., LECRUBIER, Y., PUECH, A. J., DEWAILLY, J. AND AUBIN, F.: Treatment of negative symptoms in schizophrenia with amisulpride. Br. J. Psychiat. 166: 68-72, 1995.
12. 3H-spiroperidol on rat striatal membranes. Eur. J. Pharmacol. 50: 283-284, 1978.
13. 3H]NECA in rat striatal membranes. Mol. Pharmacol. 29: 331-346, 1986.
14. CARTER, C. J. AND PYCOCK, C. J.: Behavioral and biochemical effects of dopamine and noradrenaline depletion within the medial prefrontal cortex of the rat. Brain Res. 192: 163-176, 1980.
15. CARTER, C. J. AND PYCOCK, C. J.: The role of 5-hydroxytryptamine in dopamine-dependent stereotyped behaviour. Neuropharmacology 20: 261-265, 1981.
16. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108, 1973.
17. CHIVERS, J. K., GUMMEREN, W., LEYSEN, J. E., JENNER, P. AND MARSDEN, C. D.: Comparison of the in vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. J. Pharm. Pharmacol. 40: 415-421, 1988.
18. CHRISTENSEN, A., FJALLAND, B. AND MOLLER-NIELSEN, I.: On the supersensitivity of dopamine receptors induced by neuroleptics. Psychopharmacology 48: 1-6, 1976.
19. CLAUSTRE, Y., FADE, D., ZIVKOVIC, B. AND SCATTON, B.: Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors. J. Pharmacol. Exp. Ther. 232: 519-525, 1985.
20. COSTALL, B., NAYLOR, R. J. AND NOHRIA, V.: Climbing behaviour induced by apomorphine in mice: A potential model for the detection of neuroleptic activity. Eur. J. Pharmacol. 50: 39-50, 1978.
21. DADKAR, N. K., DOHADWALLA, A. N. AND BHATTACHARYA, B. K.: Influence of pheniramine and chlorpheniramine on apomorphine-induced compulsive gnawing in mice. Psychopharmacology 48: 7-10, 1976.
22. DELCKER, A., SCHOON, M. L., OCZKOWSKI, B. AND GAERTNER, H. J.: Amisulpride versus haloperidol in the treatment of schizophrenic patients-Results of a double-blind study. Pharmacopsychiatry 23: 125-130, 1990.
23. DEMCHYSHYN, L. L., SUGAMORI, K. S., LEE, F. J. S., HAMADANIZADEH, S. A. AND NIZNIK, H. B.: The dopamine D1D receptor-Cloning and characterization of three pharmacologically distinct D1-like receptors from Gallus domesticus. J. Biol. Chem. 270: 4005-4012, 1995.
24. DI CHIARA, G., CORSINI, G. U., MEREU, G. P., TISSARI, A. AND GESSA, G. L.: Self-inhibitory dopamine receptors: Their role in the biochemical and behavioural effects of low doses of apomorphine. Dopamine, ed. by P. J. Roberts, G. N. Woodruff and L. L. Iversen, pp. 275, Raven Press, New York, 1986.
25. 1-adrenoceptor classification. Eur. J. Pharmacol. 268: 141-149, 1994.
26. FERRIS, C. D., HIRSCH, D. J., BROOKS, B. P. AND SNYDER, S. H.: σ Receptors: From molecule to man. J. Neurochem. 57: 729-737, 1991.
27. GIFFORD, A. N. AND JOHNSON, K. M.: A pharmacological analysis of the effects of (+)-AJ 76 and (+)-UH 232 at release regulating pre- and postsynaptic dopamine receptors. Eur. J. Pharmacol. 237: 169-175, 1993.
28. GLOSSMANN, H., BAUKAL, A. J. AND CATT, K. J.: Properties of angiotensin II receptors in the bovine and rat adrenal cortex. J. Biol. Chem. 249: 825-834, 1974.
29. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J. Pharmacol. Exp. Ther. 275: 899-913, 1995.
30. 4 receptors in guinea-pig and rat brain. Br. J. Pharmacol. 109: 618-624, 1993.
31. 1D receptors in human prefrontal cortex and caudate: Interaction with a GTP binding protein. J. Neurochem. 51: 1906-1912, 1988.
32. 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes. J. Neurosci. 7: 894-903, 1987.
33. HICKS, P. E., SCHOEMAKER, H. AND LANGER, S. Z.: 5HT-receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain. Eur. J. Pharmacol. 105: 339-342, 1984.
34. B sites in rat brain. Nature (Lond.) 290: 149-152, 1981.
35. 3H]AMPA, a structural analogue of glutamic acid, to rat brain membranes. J. Neurochem. 38: 173-178, 1982.
36. HONORÉ, T. AND DREJER, J.: Chaotropic ions affect the conformation of quisqualate receptors in rat cortical membranes. J. Neurochem. 51: 457-461, 1988.
37. IMPERATO, A. AND DI CHIARA, G.: Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis. Eur. J. Pharmacol. 156: 385-393, 1988.
38. 3H-GBR-12935 binding in brain: A radioligand for selective labelling of the dopamine transport complex. J. Neurochem. 48: 1272-1276, 1986.
39. JOHANSSON, A. M., ARVIDSSON, L. E., HACKSELL, U., NILSSON, J. L. G., SVENSSON, K., HJORTH, S., CLARK, D., CARLSSON, A., SANCHEZ, D., ANDERSSON, B. AND WIKSTRÖM, H.: Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors. J. Med. Chem. 28: 1049-1053, 1985.
40. KISHIMOTO, H., SIMON, J. R. AND APRISON, M. H.: Determination of the equilibrium dissociation constants and number of glycine binding sites in several areas of the rat central nervous system, using a sodium-independent system. J. Neurochem. 37: 1015-1024, 1981.
41. 3H-raclopride, a potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem. Pharmacol. 34: 2251-2259, 1985.
42. KÖHLER, C., RADESÄTER, A. C., KARLSSON-BOETHIUS, G., BRYSKE, B. AND WILDMAN, M.: Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain. J. Neural Transm. 87: 49-62, 1992.
43. LADURON, P. M., JANSSEN, P. F. M. AND LEYSEN, J. E.: Spiperone: A ligand of choice for neuroleptic receptors. 2. Regional distribution and in vivo displacement of neuroleptic drugs. Biochem. Pharmacol. 27: 317-321, 1978.
44. LANGER, S. Z., ARBILLA, S., SCATTON, B., ZIVKOVIC, B., GALZIN, A. M., LLOYD, K. G. AND BARTHOLINI, G.: Progabide and SL 75.102: Interaction with GABA receptors and effects on neurotransmitter and receptor systems. In Epilepsy and GABA Receptor Agonists, ed. by G. Bartholini, L. Bossi, K. G. Lloyd and P L. Morselli, pp. 81-90, Raven Press, New York. 1985.
45. 3H]cirazoline to an imidazoline site in rat brain and kidney membranes. Eur. J. Pharmacol. 278: 261-264, 1995.
46. 3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur. J. Pharmacol. 275: R7-R9, 1995.
47. 2 receptors. Psychopharmacology (Berl) 112: S40-S54 1993.
48. 3 receptors. Mol. Pharmacol. 43: 749-754, 1993.
49. 3 receptors. Eur. J. Pharmacol. 249: R5-R6, 1993.
50. MELTZER, H. Y.: The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17: 263-287, 1991.
51. MELTZER, H. Y.: New drugs for the treatment of schizophrenia. Psychiatr. Clin. North Am. 16: 365-385, 1993.
52. 1 values. J. Pharmacol. Exp. Ther. 251: 238-246, 1989.
53. MOGILNICKA, E., SCHEEL-KRUGER, J., KLIMEK, V. AND GOLEMBIOWSKA-NIKITIN, K.: The influence of antiserotonergic agents on the action of dopaminergic drugs. Pol. J. Pharmacol. Pharm. 20: 31-38, 1977.
54. 3H-imipramine binding sites in the rat cerebral cortex. Eur. J. Pharmacol. 65: 289-292, 1980.
55. 3 receptor antisense influences dopamine synthesis in rat brain. NeuroReport 6: 573-576, 1995.
56. PAILLERE MARTINOT, M. L., LECRUBIER, Y., MARTINOT, J. L. AND AUBIN, F.: Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am. J. Psychiatry 152: 130-134, 1995.
57. PARKER, E. M. AND CUBEDDU, L. X.: Evidence for autoreceptor modulation of endogenous dopamine release from rabbit caudate nucleus in vitro. J. Pharmacol. Exp. Ther. 232: 492-500, 1985.
58. 3H]Batrachotoxinin A 20-α-benzoate binding to sodium channels in rat brain: Characterization and pharmacological significance. Eur. J. Pharmacol. 124: 291-298, 1986.
59. PAXINOS, G. AND WATSON, C.: The Rat Brain in Stereotaxic Coordinates. Academic Press, Sydney, Australia, 1982.
60. PAZOS, A., HOYER, D. AND PALACIOS, J. M.: The binding of serotonergic ligands to the porcine choroid plexus: Characterization of a new type of serotonin recognition site. Eur. J. Pharmacol. 106: 539-546, 1984.
61. 1C binding sites in rat frontal cortex. J. Neurochem. 47: 529-540, 1986.
62. 3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol. Exp. Ther. 1997.
63. 3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur. J. Pharmacol.-Molec. Pharm. 268: 129-139, 1994.
64. 3H]clonidine binding in rat submaxillary glands. Eur. J. Pharmacol. 82: 85-88, 1982.
65. 3H]desipramine binding in the peripheral and central nervous system: A specific site associated with the neuronal uptake of noradrenaline. Eur. J. Pharmacol. 78: 345-351, 1982.
66. 3H-labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc. Natl. Acad. Sci. U.S.A. 84: 7744-7748, 1987.
67. SALETU, B., KUFFERLE, B., GRUNBERGER, J., FOLDES, P., TOPITZ, A. AND ANDERER, P.: Clinical, EEG mapping and psychometric studies in negative schizophrenia: Comparative trials with amisulpride and fluphenazine. Neuropsychobiology 29: 125-135, 1994.
68. 1A receptors. Psychopharmacology 108: 85-92, 1992.
69. 1 receptors. NeuroReport 6: 329-332, 1995.
70. SCATTON, B., BISCHOFF, S., DEDEK, J. AND KORF, J.: Regional effects of neuroleptics on dupamine metabolism and dopamine-sensitive adenylate cyclase activity. Eur. J. Pharmacol. 44: 287-292, 1977.
71. 3 receptors. Neuropsychopharmacology 10: 242S, 1994.
72. SCATTON, B. AND ZIVKOVIC, B.: Neuroleptics and the limbic system. In Psychopharmacology of the Limbic System, ed. by M. R. Trimble and E. Zarifian, pp. 174-197, Oxford University Press, Oxford, 1985.
73. 2A receptors in antipsychotic activity. Life Sci. 56: 2209-2222, 1995.
74. 3 receptors and σ sites in the bovine caudate nucleus. Eur. J. Pharmacol. 242: R1-R2, 1993.
75. 3H]Ro 5-4864 in rat brain and kidney. J. Pharmacol. Exp. Ther. 225: 61-69, 1983.
76. 3 autoreceptors. (Abstract) Soc. Neurosci. 21: 1995.
77. 3H]8-OH-DPAT labels the serotonin transporter in the rat striatum. Eur. J. Pharmacol. 124: 371-373, 1986.
78. 3H]diltiazem binding and its allosteric interaction with dihydropyridine calcium channel binding sites in the rat cortex. J. Pharmacol. Exp. Ther. 248: 710-715, 1989.
79. 3H]ifenprodil, and NMDA antagonist, to polyamine and sigma sites in the cerebral cortex. FASEB J. 5: A703, 1991.
80. 6-phenyliaopropyladenosine. Naunyn Schmiedeberg Arch. Pharmacol. 313: 179-187, 1980.
81. 4. Nouropaychopharmacology 7: 261-284, 1992.
82. SERMERDJIAN-ROUQUIER, L., Bossi, L. AND SCATTON, B.: Determination of 5-hydroxytryptophan, serotonin and 5-hydroxyindoleacetic acid in rat and human brain and biological fluids by reveraed-phase high-performance liquid chromatography with electrochemical detection. J. Chromatog. 218: 663-670, 1981.
83. 3H]CGP 39653: A new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain. Eur. J. Pharmacol. 192: 19-24, 1991.
84. 3H]kainic acid, an analogue of L-glutamate, to brain membranes. J. Neurochem. 26: 141-147, 1976.
85. 2 receptor. Eur. J. Pharmacol. 225: 331-337, 1992a.
86. 3 dopamine receptor. Arzneimittelforschung 42: 224-230, 1992b.
87. 3) as a target for neuroleptics. Nature (Lond.) 347: 146-151, 1990.
88. 3) as a novel target for antipsychotics. Biochem. Pharmacol. 43: 659-666, 1992c.
89. 2 receptors. J. Pharmacol. Exp. Ther. 266: 1374-1384, 1993.
90. SUAUD-CHAGNY, M. F., PONEC, J. AND GONON, F.: Presynaptic autoinhibition of the electrically evoked dopamine release studied in the rat olfactory tubercle by in vivo electrochemistry. Neuroscience 45: 641-652, 1991.
91. SUGAMORI, K. S., DEMCHYSHYN, L. L., CHUNG, M. AND NIZNIK, H. B.: D-1A, D-1B, and D-1C dopamine receptors from Xenopus laevis. Proc. Natl. Acad. Sci. U.S.A. 91: 10536-10540, 1994.
92. 1. Nature (Lond.) 350: 614-619, 1991.
93. SVENSSON, K., JOHANSSON, A. M., MAGNUSSON, T. AND CARLSSON, A.: (+)-AJ76 and (+)-UH232: Central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn-Schmiedeberg's Arch. Pharmacol. 334: 234-245, 1986.
94. 3 receptors. Eur. J. Pharmacol. 263: 235-243, 1994.
95. 5-containing omega (BZ) receptor subtype in the neonatal rat cerebral cortex. Br. J. Pharmacol. 108: 295P, 1993.
96. TIMMERMAN, W., DE VRIES, J. B. AND WESTERINK, B. H. C.: Effects of D-2 agonists on the release of dopamine: Localization of the mechanism of action. Naunyn Schmiedebergs Arch. Pharmacol. 342: 650-654, 1990.
97. 3H]mepyramine. Proc. Natl. Acad. Sci. U.S.A. 73: 6290-6294, 1970.
98. A receptor complex. Eur. J. Pharmacol. 179: 419-425, 1990.
99. 4 receptor with high affinity for the antipsychotic clozapine. Nature (Lond.) 350: 610-614, 1991.
100. VARGAS, F., THURET, F. AND LLOYD, K. G.: Characterization of the nipecotic binding to rat brain membranes. Gen. Pharmacol. 24: 321-327, 1993.
101. VASSE, M., PROTAIS, P., COSTENTIN, J. AND SCHWARTZ, J.-C.: Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice. Naunyn Schmiedebergs Arch. Pharmacol. 329: 108-116, 1985.
102. WALTERS, J. R. AND ROTH, R. H.: Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors. Naunyn Schmiedebergs Arch. Pharmacol. 296: 5-14, 1976.
103. 3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; A microdialysis study. Eur. J. Pharmacol. 242: 151-163, 1993a.
104. WATERS, N., HANSSON, L., LÖFBERG, L. AND CARLSSON, A.: Intracerebral infusion of (+)-AJ76 and(+)-UH232: Effects on dopamine release and metabolism in vivo. Eur. J. Pharmacol. 251: 181-190, 1994.
105. WATERS, N., SVENSSON, K., HAADSMA-SVENSSON, S. R., SMITH, M. W. AND CARLSSON, A.: The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity. J. Neural. Tranam. 94: 11-19, 1993b.
106. WISZNIOWSKA-SZAFRANIEC, G. L., BANEK, K., REICHENBERG, K. AND VETULANl, J.: Facilitation by alpha-adrenolytics of apomorphine gnawing behaviour: Depression of threshold apomorphine concentration in the striatum of the rat. Pharmacol. Biochem. Behav. 19: 19-22, 1983.
107. 3H]MK-801 labels a site on the N-methyl-D-aspartato receptor channel complex in rat brain membranes. J. Neurochem. 50: 274-281, 1988.
108. 1c site from pig choroid plexus. Mol. Pharmacol. 29: 120-125, 1986.
109. YAMAMURA, H. I. AND SNYDER, S. H.: Muscarinic cholinergic binding in rat brain. Proc. Natl. Acad. Sci. U.S.A. 71: 1725-1729, 1974.
110. YOUNG, A. B. AND SNYDER, S. H.: Strychnine binding associated with glycine receptors of the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 70: 2832-2836, 1973.
111. YOUNG, A. B. AND SNYDER, S. H.: The glycine synaptic receptor: Evidence that strychnine binding is associated with the ionic conductance mechanism. Proc. Natl. Acad. Sci. U.S.A. 71: 4002-4005, 1974.
112. ZUKIN, S. R., YOUNG, A. B. AND SNYDER, S. H.: Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system. Proc. Natl. Acad. Sci. U.S.A. 71: 4802-4807, 1974.